TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00634088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
Description: Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
Description: Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
Description: Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone + Lapatinib + Capecitabine
Description: Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
Study: NCT03689166

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Reduce preterm birth with this dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02592746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg, orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Leuprolide Acetate 3.75mg SC q 4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
Study: NCT03000699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
Study: NCT01238614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA PSF plus JIT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA maternal depression PSF

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01389180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and HIV Risk Reduction Counseling
Description: BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Counseling
Description: EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
Study: NCT04361162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 3D Conformal Radiotherapy to shrink or kill tumors
Study: NCT01936935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Description: 2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar-sweetened beverages
Description: 2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
Study: NCT04176276

Intervention type: OTHER
Intervention: no interventions required.
Description: The study does not require any interventions.
Study: NCT00149409

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omacor
Study: NCT00211692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: consensus interferon (Interferon Alfacon-1) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consensus Interferon alfa (CIFN) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consensus Interferon alfa (CIFN) and ribavirin
Description: CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
Study: NCT03017066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Scheduled operation under general anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Scheduled operation under general anesthesia
Study: NCT04309175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: base rate programming of a permanent cardiac pacemaker
Description: Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
Study: NCT00149409

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omacor
Study: NCT02918045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing
Description: The Hemcon Dental Dressing is an oral wound dressing made of chitosan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidized Cellulose Gauze
Description: A common hemostatic measure after dental extractions placed into the extraction socket.
Study: NCT01990183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareToy
Description: Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Current care advices in the management of preterm infants in the first months of life
Study: NCT01272349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia
Description: 30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: 30 minutes of breathing room air followed by walking on a body-weight support treadmill
Study: NCT01590056

Intervention type: OTHER
Intervention: Electrophysiological recording
Description: During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test
Study: NCT00158275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants
Description: Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
Study: NCT03471494

Intervention type: OTHER
Intervention: Exposure: human development index of country
Description: Primary comparison: Between country groups defined by human development index.

Intervention type: OTHER
Intervention: Exposure: human development index of country
Description: Primary comparison: Between country groups defined by human development index.

Intervention type: OTHER
Intervention: Exposure: human development index of country
Description: Primary comparison: Between country groups defined by human development index.
Study: NCT03650387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RADIESSE® (+) Lidocaine
Description: RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
Study: NCT03596684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose tolerance test
Description: 2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
Study: NCT04306081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
Study: NCT00646399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
Study: NCT01227941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827 + pegylated liposomal doxorubicin
Description: Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
Study: NCT00646399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab 50 mg/mL
Description: Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
Study: NCT03680300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Facilitation Stretch
Description: The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation
Description: The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friction Massage
Description: Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
Study: NCT00723060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
Study: NCT01988844

Intervention type: OTHER
Intervention: Assessment
Description: The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
Study: NCT00052013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Study: NCT01243047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Erlotinib, Oxaliplatin, Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Erlotinib, Oxaliplatin, Capecitabine
Study: NCT00851721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Description: 85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Description: FEIBA NF dose and dosing interval as prescribed by the treating physician
Study: NCT01791088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01618929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
Study: NCT04359147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine + Hydrocortisone
Description: Effects on neural correlates of decision-making under risk and selective attention to threat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effects on neural correlates of decision-making under risk and selective attention to threat
Study: NCT00801502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oily fish consumption
Description: Two portions of salmon per week from week 20 of pregnancy until giving birth

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No change to habitual diet from week 20 of pregnancy until giving birth
Study: NCT03851029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints
Study: NCT01988129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep disorders education and screening
Description: Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
Study: NCT00714194

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Normal continuous sedation
Description: Normal continuous sedation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily interruption of continuous sedation
Description: Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
Study: NCT01396512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis chimeric virus vaccine
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)
Description: 0.5 mL, Subcutaneous
Study: NCT03394469

Intervention type: OTHER
Group type: OTHER
Intervention: collection
Description: Blood, urinary and faecal samples
Study: NCT03657186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProbioSatys™
Description: One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
Study: NCT04306081

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
Study: NCT04364399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mumps vaccine
Description: One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
Study: NCT02703480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: d-PTFE
Description: high-density polytetrafluoroethylene (d-PTFE) membrane

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ti-mesh
Description: Titanium mesh
Study: NCT02516592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 micrograms
Description: QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 microgrammes
Description: Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device